We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New Multiplex Real-time PCR Kits Detect Clinically Relevant β-lactamase Genes
Product News

New Multiplex Real-time PCR Kits Detect Clinically Relevant β-lactamase Genes

New Multiplex Real-time PCR Kits Detect Clinically Relevant β-lactamase Genes
Product News

New Multiplex Real-time PCR Kits Detect Clinically Relevant β-lactamase Genes

Credit: Alpha Laboratories

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "New Multiplex Real-time PCR Kits Detect Clinically Relevant β-lactamase Genes"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

β-lactamase enzymes inactivate β-lactam antibiotics and render them ineffective for the treatment of clinically-important Gram-negative bacterial infections. Now, two new kits from Streck Inc., available in the UK from Alpha Laboratories Ltd., provide a comprehensive, cost-effective molecular method to detect the most clinically-important β-lactamases that confer resistance to penicillins, cephamycins, and in some cases, carbapenems.

The antibiotic resistance monitoring and detection (ARM-D) kits, are multiplex real-time PCR kits that can quickly detect more than 450 β-lactamase gene variants. The ARM-D® Kit, β-Lactamase detects 9 different Carbapenemases, ESBLs and plasmid-mediated ampC gene families. The ARM-D® Kit, ampC kit targets 6 plasmid-mediated ampC resistance gene families and can differentiate plasmid-mediated ampC β-lactamase resistance from chromosomal resistance.

These genotypic detection methods identify the most prevalent types of β-lactamase-based antibiotic resistance and complement phenotypic methods for the detection of multidrug resistant organisms. They can be used with standard susceptibility tests to improve surveillance and epidemiologic tracking, for improved infection control and increased effectiveness of antibiotic stewardship programs.

AmpC β-lactamases are chromosomally encoded in many bacterial species. Their overexpression can lead to resistance to most β-lactam antibiotics, causing therapeutic failure. Transmissible plasmids with acquired genes for AmpC β-lactamases often cause increased β-lactamase production and can appear in organisms lacking or having low-level expression of a chromosomal ampC gene. Resistance due to plasmid-mediated AmpC enzymes can be broad in spectrum and often hard to detect.

As Gram-negative organisms producing multiple or plasmid-mediated β-lactamases are difficult to identify phenotypically, more specific detection methods are essential for the identification of clinically important β-lactamases and selection of the appropriate antibiotic therapy. Detection and genetic identification of both plasmid-mediated and chromosomally expressed AmpC β-lactamases are crucial for better understanding of these resistance mechanisms and, consequently, for active surveillance and infection control. 

Advertisement